About the Authors:
Saurabh Singh
Affiliation: Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
Deepak Chitkara
Affiliations Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, SAS Nagar (Mohali), Punjab, India
Reza Mehrazin
Affiliation: Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
Stephen W. Behrman
Affiliation: Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
Robert W. Wake
Affiliation: Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
Ram I. Mahato
* E-mail: [email protected]
Affiliation: Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
Introduction
Prostate cancer is the second leading cause of cancer related death in men in the United States [1]. While anti-androgen therapy is currently the first line of treatment for patients diagnosed with prostate cancers, most patients will eventually develop the androgen-independent form of prostate cancers which is highly metastatic and has poor prognosis [2]. Microtubule stabilizers such as PTX are effective in treating patients diagnosed with androgen-independent prostate cancer [3]. While clinical trials have proven the initial efficacy of taxanes in increasing survival in prostate cancer patients [4], there are currently few effective approaches for treating chemoresistant prostate cancers.
Most tumors are heterogeneous and are composed of bulk and tumor initiating cells (TICs) with the latter forming a distinct subpopulation in many cancers. TICs are often referred to as cancer stem cells (CSCs) and are responsible for tumor initiation, self-renewal, and chemoresistance [5], [6]. Many prostate cancers relapse due to the presence of highly chemoresistant tumor initiating/cancer stem cells [7], [8]. Chemoresistance to anticancer drugs including PTX, by these cells may be contributed by drug-efflux pumps which can efficiently remove lipophilic molecules, including hydrophobic anticancer drugs. This inherent property of chemoresistant cells is used for identification and isolation of a side population (SP), which are a type of cancer stem cells. The SP fraction, initially identified by Goodell, is a small subpopulation of cells with enriched stem cell activity and are known to demonstrate distinctively low levels of Hoechst 33342 dye staining [9]. SP fraction cells have been shown to be insensitive to various chemotherapeutic drugs [10] owing to their ability in effluxing chemotherapy drugs (and lipophilic dyes such as Hoechst 33342) due to the high expression of ATP-binding cassette family, such as MDR1 (P-glycoprotein) and ABCG2 [11]. Chemoresistant SP cells will survive and sustain their clonogenicity during initial exposure to cytostatic drugs, thereby allowing disease recurrence when therapy is withdrawn. These subsets of CSCs are thus considered a viable target for improved therapeutic intervention and preventing chemoresistance and cancer relapse.
The development of chemoresistance through an increase in the number of cancer stem like cells, including SP fractions has been attributed to alterations at the level of microRNAs (miRNAs) in various cancer types. These non-coding RNA molecules can act as oncogenes as well as tumor suppressor [12], [13], [14]. Dysregulation of miRNAs has been implicated in tumorigenesis and drug resistance as well. Recent work by Cochrane et al. has identified miRNAs involved in modulating chemoresistance in several cancers [15].
In our present study, we hypothesized that chemoresistance to PTX in metastatic prostate cancer cells could be due to the altered miRNA expression in these cells and that the combination of antimitotic drug with another small molecule that inhibits CSCs is likely to be effective in not only reverting chemoresistance by suppressing CSCs but also target miRNAs involved in chemoresistance. Thus, while failure of traditional chemotherapy is due to a failure to destroy CSCs/SP fractions, a combinatorial approach is likely to yield better results since the CSC-inhibitor will kill pluripotent cancer cells and will allow the antimitotic drug (in this case PTX) to attack bulk tumor cells. Towards this end, we have combined PTX with cyclopamine (CYA), a natural steroidal alkaloid which inhibits the Hedgehog (Hh) pathway resulting in decreased proliferation and increased apoptosis [16]. In recent years, the Hh signaling pathway has been implicated in the development and spread of prostate cancer [17], [18]. Evidence has also indicated that Hh signaling supports androgen signaling and androgen-independent growth in prostate cancer cells in a low androgen environment [19]. Inhibition of Hh-pathway results in downregulation of genes involved in stem cell self-renewal as well as regression of prostate tumor without relapse [20]. Combination of docetaxel with CYA and epidermal growth factor receptor (EGFR) inhibitor gefitinib induced greater antiproliferative and apoptotic effects on SP cell fractions isolated from metastatic prostate cancer cells than individual drugs [21]. We have recently demonstrated that adding EGFR-inhibitor lapatinib can enhance the effectiveness of PTX in inducing apoptosis in a paclitaxel-resistant, androgen-independent metastatic prostate cancer cells line DU145-TXR, both in vitro as well as in xenograft tumors [22].
To understand the phenomenon of chemoresistance, in the present study we have used androgen independent (AI) metastatic prostate cancer cell lines DU145 and PC3 and their PTX-resistant versions, DU145-TXR and PC3-TXR, respectively. We have shown that PTX resistance of prostate cancer cells may be modulated at the level of miRNAs. We further demonstrate that combination therapy with CYA and PTX can effectively reduce cell viability, decrease SP-cell fraction at doses far lower than that used for CYA monotherapy and impact miRNAs putatively involved in modulating chemoresistance. Our data indicates that combination therapy involving supplementation of PTX with Hh-inhibitors can target specific miRNAs and cancer stem-cell like SP cell populations at doses that are effective in combination but not in monotherapy. This approach may represent a better approach in preventing metastasis and relapse in refractory prostate cancer since it is less likely to be toxic and will present with far fewer side effects for the patient, ensuring better compliance and reducing the chances of a recurrence.
Materials and Methods
Materials
PTX and CYA were purchased from LC Labs (Woburn, MA). SYBR Green real-time PCR master mix and reverse transcription reagents were purchased from Applied Biosystems (Foster city, CA). Goat anti-rabbit P-gp antibody and corresponding secondary antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO) and used as received, unless stated otherwise.
Cell lines
The human metastatic prostate cancer cell lines DU145 and PC3 and their PTX resistant versions DU145-TXR and PC3-TXR were a kind gift of Prof. Evan T. Keller (University of Michigan). All cell lines were maintained in RPMI culture media supplemented with 1% penicillin/ streptomycin and 10% fetal bovine serum (FBS) (Gibco) in a humidified incubator containing 5% CO2 at 37°C as described earlier [22].
Human Prostate Tissue
Human prostate tissue (cancerous and benign) were obtained from the Veterans Affairs (VA) Hospital, Memphis, TN following established protocols and in accordance with the informed consent waiver provided by the Institutional Review Board (IRB) at UTHSC and at the VA Hospital. Prostate tissue was taken using an 18-gauge core needle biopsy gun and a portion of this tissue was rinsed and either flash frozen in liquid nitrogen and then stored at −80°C or placed in cold serum-free RPMI media containing antibiotics for preparing single cell suspensions. Tissues were classified as malignant or benign based on the diagnosis made by a pathologist.
Drug sensitivity and apoptosis assays in DU145-TXRCells
To determine the extent of cellular apoptosis following drug treatments, DU145-TXR cells were plated into 6-well plates (7.5×105 cells/well). After 24 h, the media was removed and fresh media containing varying concentrations of PTX, CYA or their combinations were added. The cells were then stained with Annexin-V and Propidium iodide (PI) using the Vybrant Apoptosis Assay Kit as per the manufacturer's protocol (Molecular Probes). Briefly, cells were trypsinized, washed twice with cold PBS and pelleted by centrifugation at 800 rpm for 5 min. The pellets were resuspended in 100 μl of 1X Annexin binding buffer and 5 μl fluorescein isothiocyanate (FITC)-Annexin-V. Propidium iodide (100 μg/ml) was added to each 100 μl of cell suspension. The stained cells were immediately analyzed by flow cytometry.
DU145-TXR cells were also used to determine the cell growth inhibition ability of PTX and CYA. Cells (5×103/well) were seeded in 96 well cell culture plates and incubated for 24 h to allow cell attachment. Media was then replaced with fresh media containing PTX (0.5/1 µM) or CYA (10/25 µM) or combination (PTX 0.5 µM and CYA 10µM) and incubated further for 48 h at 37°C/5% CO2. Cell viability was then assessed by MTT assay. For this, media was removed and cells were washed with PBS and 200 µl of fresh media containing 3-(4,5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) (0.5 mg/ml) was added followed by incubation at 37°C/5% CO2 for 4 h. After 4 h, media was removed and formed formazan crystals were dissolved in 200 µl DMSO and absorbance was measured at 560 nm. Cell viability was calculated using the following formula:
DMSO was used to solubilize PTX and CYA and DMSO controls were included in all experiments.
Side Population analysis and cell sorting by FACS
Side population analysis in DU14-TXR and PC3-TXR cell lines was performed using Hoechst 33342 flow cytometry method. In brief, adherent cells were trypsinized and washed with phosphate buffered saline (PBS). Cells (1×106 cell/ml) were then suspended in RPMI media supplemented with 2% FBS and 1 mM HEPES buffer with or without drug solutions (Verapamil, PTX or PTX+CYA). Hoechst 33342 (5 µl; 1 mg/ml) dye was then added followed by incubation for 90 min at 37°C. Cells were recovered by centrifugation and washed several times with PBS to remove unbound dye and finally suspended in ice cold PBS containing 2% FBS. SP fraction in clinical samples was analyzed as described above with additional steps. Briefly, freshly resected prostate tissue was rinsed, mechanically minced and digested for 4 h at 37°C with 100 U/ml collagenase IV (Worthington Biologicals) in serum free RPMI. The tissue was frequently pipetted with a 5-ml serological pipette and at the end of incubation the digest was passed through an 18.5- gauge needle, centrifuged briefly and the supernatant sieved through a 100 µm cell strainer to obtain single cell suspension. Diluted single cell suspensions were then passed once through 40 µm mesh filter, their viability assessed by trypan blue staining and kept on ice until analyzed.
[Figure omitted. See PDF.]
Figure 1. Effect of PTX and CYA combination on viability of PTX resistant DU145-TXR cells.
Cells grown in 6-well plates were treated with A) 0.3% DMSO, B) 0.5 µM PTX C) 10 µM CYA, D) 25 µM CYA, E) 0.5 µM PTX +10 µM CYA for 48h and F) in DU145-TXR cells after different drug treatments. Subsequently, cells were trypsinized, washed with PBS and stained with Annexin V-FITC and PI before apoptotic analysis by flow cytometry. A–E are representative plots from three individual experiments. Data in panel F is the quantitation of % cell death and represents mean ± SD (n = 3). *p<0.05 vs. control. For MTT assay (Fig. 1G), cells grown in 96 well plate were treated with indicated concentration of drugs for 48 h. Subsequently, MTT reagent in PBS was added and incubation was carried out for another 4 h. The resulting formazan product was solubilized in DMSO and the color intensity was determined using a plate reader. A statistically significant difference (* p value <0.05) was observed when combination of 0.5 µM PTX and 10 µM CYA was used. Cell Viability = Atest/AcontrolX100. Data are the means±SD (n = 4). PTX, Paclitaxel; CYA, Cyclopamine.
https://doi.org/10.1371/journal.pone.0040021.g001
Cell Cycle analysis
Flow cytometry was used to determine the percentage of cells in different growth cycles. Cells (5×105) obtained after sorting were washed with PBS and fixed with ethanol (70%) at 4°C overnight followed by treatment with RNAse (1 mg/ml) and stained with PI (10 µg/ml). Percentage of cells in different cell cycle phases was then determined.
[Figure omitted. See PDF.]
Figure 2. Analysis of side population (SP) fraction in PTX resistant DU145 TXR cells after treatment with PTX and CYA.
A) DU145 cells, B) DU145-TXR cells, C) DU145-TXR cells treated with verapamil (10 µM, 90 min), D) DU145-TXR cells treated with PTX (1 µM, 12 h), E) DU145-TXR cells treated with CYA (20 µM, 12 h), F) DU145-TXR cells treated with CYA and PTX (20 µM and 0.5µM, respectively, 12 h). Verapamil was used to gate the SP fraction in all panels and shown as the percentage of the whole viable cell population. Numerical values indicated are the mean±SD of three individual experiments. * p<0.05 vs control DU145 cells in (A). PTX, Paclitaxel; CYA, Cyclopamine.
https://doi.org/10.1371/journal.pone.0040021.g002
[Figure omitted. See PDF.]
Figure 3. Analysis of side population (SP) fraction in PTX resistant PC3-TXR cells after treatment with PTX and CYA.
A) PC3-TXR cells, B) Cells treated with verapamil (10 µM, 90 min), C) PC3-TXR cells treated with CYA (20 µM, 12 h) or, D) CYA and PTX (20 µM and 0.5µM, respectively, 12 h). The SP fraction, which was eliminated by treatment with verapamil, was gated (P8) in all panels and shown as the percentage of the whole viable cell population. Numerical values indicated are the mean±SD of three individual experiments. * p<0.05 vs control DU 145 cells (A). PTX, Paclitaxel; CYA, Cyclopamine.
https://doi.org/10.1371/journal.pone.0040021.g003
[Figure omitted. See PDF.]
Figure 4. Post differentiation fate of side population fractions from DU145-TXR cells.
After flow sorting, pure SP cells were plated and allowed to differentiate for 2-weeks. Representative photomicrographs of SP (A) and NSP cells (B) are shown with more SP cells possessing a fibroblastic, elongated phenotype compared to NSP. Real time RT-PCR was used to confirm higher expression of stem cell markers OCT 4 and NANOG and cancer stem cell markers CD133 and ALDH1 (C). Similar method was used to show higher expression of pluripotency and efflux marker ABCG2 and lower expression of MCM7 transcripts in initial SP cells (SP), compared to mixed populations post-differentiation (DIFF) where decreased ABCG2 and increased MCM7 levels were observed (D). One set of cells was also treated with 25 µM CYA for 48h. Subsequently, cells were trypsinized and re-stained with Hoechst dye and analyzed by flow cytometry. Post-differentiation, cells derived from flow sorted SP cells had higher percentage of SP cell fractions than obtained previously from non-sorted DU145-TXR cells. CYA treatment significantly reduced (p<0.001 vs. control) the percentage of SP fraction cells from 15.8 (±2.1) % (Panel E) to 0.6±(0.09) % (Panel F). Representative dot plots from three individual experiments are provided. Data represents mean ± SD (n = 3).
https://doi.org/10.1371/journal.pone.0040021.g004
[Figure omitted. See PDF.]
Table 1. Cell Cycle distribution of SP and non-SP Cells following cell sorting.
https://doi.org/10.1371/journal.pone.0040021.t001
In vitro differentiation study
Ability of SP cells to differentiate was determined by culturing the pure cell fractions in a 6 well plate for 14 days post sorting. SP-fraction cells from DU145-TXR and PC-TXR (1×105/well) were seeded into 6 well plate and allowed to grow in RPMI culture media supplemented with 10% FBS. After 14 days, Hoechst staining and SP analysis was done on treated or untreated cell populations as described above. Gene expression analysis was also carried out on SP and non-SP cells both before and after-differentiation.
[Figure omitted. See PDF.]
Figure 5. Effect of PTX and CYA on P-gp expression in DU145-TXR cells.
Following treatment, with various drugs as described, total protein was extracted and separated by SDS-PAGE before probing with P-gp antibody. Actin was used as a loading control. A combination of 0.5 µM PTX and 10 µM CYA was more effective in downregulating P-gp expression in drug-resistant prostate cancer cells than monotherapy with either CYA or PTX at 10 and 0.5 µM concentration. P-gp downregulation with 25 µM CYA was nearly similar to that obtained by combination therapy. (B) Expression of Hh pathway and stem cell marker genes in DU145-TXR cells. Total RNA was extracted from cells and reverse transcribed to cDNA. Real time RT-PCR was carried out using SYBR Green chemistry and Ct values thus obtained were used to calculate the fold change. Drug resistant DU145-TXR cells have higher expression of all three genes tested. PTX sensitive DU145 cells were used as control and gene expression values for DU145-TXR cells were normalized with respect to the control values. *p<0.05 vs. control.
https://doi.org/10.1371/journal.pone.0040021.g005
Western blot analysis
Following treatment, DU145 TXR cells were lysed using RIPA buffer and total protein concentration was determined using Bio-Rad RC DC protein assay kit (Hercules, CA). SDS-PAGE was then performed to resolve the proteins which were then transferred to Immobilon polyvinylidene fluoride (PVDF) membrane using iBlot dry blotting system (Invitrogen, Carlsbad, CA). Blocking was done using 5% non-fat dry milk in 1X PBST (PBS containing 0.05% Tween-20) for 1 h at room temperature. Membranes were then incubated with primary antibody for 16 h at 4°C. Actin was used as the loading control and target protein was detected by enhanced chemiluminescence (ECL) detection kit (GE Healthcare Life Sciences, PA).
[Figure omitted. See PDF.]
Figure 6. miRNA profiling of prostate cancer cells and effect of combination therapy on miRNA expression.
Total RNA including miRNAs was isolated from DU145-TXR and DU145 cells (A) or PC3 and PC3-TXR cells (B) using miRNEasy RNA isolation kit. SYBR Green based pathway-focused miScript miRNA PCR Array (Qiagen, MD) was used for miRNA profiling studies. The plates were run on a Roche Light Cycler 480® instrument and the expression of individual miRNAs was analyzed using the obtained Cp values and the ΔΔCt method. Table in the insert (C) confirms validation of miRNA profiling data by miScript primer assay. Validation of miRNA profiling data was done by a SYBR Green based real time RT-PCR assay of selected miRNAs. As a normalizer, SNORD6 was used as a housekeeping miRNA. (D) Efficacy of combination therapy on restoration of miR 200 c and 34a was determined by treating DU145-TXR cells with PTX (0.5 µM) and CYA (10 µM)combination for 48 h after which total RNA was extracted, converted to cDNA and used as template for miScript primer assay for determining expression of miRNAs 200c and 34a. Untreated DU145-TXR cells were used as control for calculating fold change after a SYBR Green real time RT-PCR assay. Data represents mean ± SD (n = 3). * p<0.05 vs. untreated control.
https://doi.org/10.1371/journal.pone.0040021.g006
Real time RT-PCR
Total RNA was extracted from sorted and unsorted prostate cancer cells using RNeasy RNA isolation kit (Qiagen, MD), followed by determination of its quality by Nanodrop 2000 instrument. It was then reverse transcribed into cDNA template as described before [23]. cDNA (100 ng) was then amplified by real-time PCR using SYBR Green dye universal master mix on a Light Cycler 480 instrument (Roche, Indianapolis, IN) using the primers for genes of interest for forty cycles Relative amount of mRNA compared to S19 (housekeeping gene) level was calculated using Crossing point (Cp) values and scaled relative to control samples set at a value of 1. Results for gene expression in experimental samples were plotted compared with the control.
[Figure omitted. See PDF.]
Figure 7. Real time RT-PCR identification of gene targets of miRNA in DU145-TXR Cells.
Several genes involved in cancer related biological processes and known targets of differentially expressed miRNAs in our study are altered in PTX resistant DU145 TXR cells. Following RNA extraction and SYBR Green based real time RT-PCR using specific gene primers, Cp values were calculated and resistant DU145 cells were used to normalize the expression of individual genes. Data represents the mean ± SD (n = 3).
https://doi.org/10.1371/journal.pone.0040021.g007
MicroRNA (miRNA) profiling and data validation
Total RNA that includes small non-coding miRNA was isolated from untreated and drug-treated DU145-TXR and DU145 cells or PC3 and PC3-TXR cells using miRNEasy RNA isolation kit (Qiagen MD) following manufacturer's instructions. The same reagents were used to isolate total RNA from human prostate tissue. Briefly, flash frozen tissue was suspended in extraction buffer and subjected to careful disintegration using a hand-held electric homogenizer for 30s at a low-to-middle speed setting. The homogenate was centrifuged for 3 minutes at 4°C and the supernatant was used to extract total RNA. Post-isolation, RNA quality was determined using a Nanodrop 2000 instrument.
[Figure omitted. See PDF.]
Figure 8. SP fraction analysis and miRNA profiling of clinical prostate tissues.
(A) Human prostate cancer tissue was converted to single cell suspensions as described in ‘Methods’. Cells were stained with Hoechst dye and analyzed as described previously. Nearly 1% of total viable cell population was gated as the SP fraction. (B) Total RNA was isolated from another set of human prostate tissues (cancer and benign) using miRNEasy RNA isolation kit. SYBR Green based pathway-focused miScript miRNA PCR Array (Qiagen, MD) was used for miRNA profiling studies. The plates were run on a Roche Light Cycler 480® instrument and the expression of individual miRNAs was analyzed using the obtained Ct values and the ΔΔCt method. The fold changes in the tumor tissues were normalized with respect to the benign prostate tissue. (C) Table in the insert confirms validation of miRNA profiling data by miScript primer assay. Validation of miRNA profiling data was done by RT-PCR estimation of selected miRNAs200c, 34a and 29b. SNORD6 was used as a housekeeping miRNA for data normalization.
https://doi.org/10.1371/journal.pone.0040021.g008
For miRNA profiling studies, SYBR green based pathway-focused miScript miRNA PCR Array (Qiagen, MD) was used. The cancer pathway array (catalog number 102ZF) allows the simultaneous detection of 84miRNAs previously identified in human cancers, as well as appropriate housekeeping assays and RNA quality controls. The assay was performed according to the manufacturer's protocol. Three hundred nanograms (ng) of total RNA were converted to cDNA using miScript II RT Kit. Diluted cDNA was mixed with universal primer and SYBR Green dye and added to the wells of 96-well plates containing lyophilized primer. The plates were run on a Roche Light Cycler 480®instrument and the expression of individual miRNAs was analyzed using the obtained Ct values. The fold change for each miRNA was calculated by plugging the Cp values into the manufacturer's web-based software. DU145 cells or PC3 cells, as well as benign prostate samples were considered as ‘controls’ in order to calculate the fold change in DU145-TXR and PC3-TXR cells and cancerous prostate tissue, respectively. Endogenous controls, RT negative and positive controls, and genomic DNA contamination controls were also tested for each array.
[Figure omitted. See PDF.]
Figure 9. Interrelationship between EMT, cancer stem cells, miRNA and chemoresistance.
Significant interrelationship exists between chemoresistance, epithelial to mesenchymal transition and metastasis, which adversely impacts treatment outcomes. Chemoresistance, a key feature of CSCs and cells undergoing EMT, is regulated by the dysregulation of miRNAs. Our proposed combination therapy with PTX and CYA simultaneously targets CSCs and bulk cancer cells, reverses EMT and restores expression of miRNAs altered during generation of chemoresistance and is a viable strategy for treating drug-resistant prostate cancer.
https://doi.org/10.1371/journal.pone.0040021.g009
Validation of miRNA profiling data was done by real-time PCR estimation of selected miRNAs. For each of the selected miRNA, a miScript PCR primer was purchased from Qiagen. This assay targets only mature miRNAs, not their precursors. As a normalizer, SNORD6 was used as a housekeeping miRNA. Briefly, diluted cDNA used for miRNA profiling was used as a template in the presence of SYBR Green dye, universal primer and miScript primer. The plate was run as described above and fold changes in miRNA expression were calculated using the Ct value of the normalizer control. A similar approach was used to measure expression of miR200c and miR 34a in DU 145-TXR cells treated with 0.5 µM PTX+10 µM CYA. After treatment, total RNA was isolated, reverse transcribed to cDNA and used to measure miRNA expression as described above.
Statistical Analysis
All values in the figures and text were expressed as the mean ± SD. The results were analyzed and individual group means were compared with Student's unpaired t-test. A p value of at least 0.05 was considered significant and is indicated by an asterisk (*).
Results
Combination of CYA and PTX reduces cell viability and enhances apoptosis in drug-resistant prostate cancer cells
The ability of combination chemotherapy to inhibit the growth of PTX resistant prostate cancer cell line was assessed by cell viability and apoptosis assay. It was observed that combination of PTX and CYA significantly (p value<0.05) decreases cell viability to 40% as compared to either PTX or CYA alone (Fig. 1, panels A–F). Similar results were obtained in Annexin V cell death assay wherein combination therapy results in a significantly higher cell death as compared to single agent chemotherapy (Fig. 1, G). While a combination of PTX and CYA resulted in nearly 70% of cells dying, the percent cell death observed with PTX or CYA monotherapy was 15% and 25% respectively. However, treatment with 25 µM CYA was significantly more effective than control and resulted in nearly 40% cell death.
Side Population fractions exist in PTX -resistant prostate cancer cells and have unique gene expression
Figures 2 and 3 show the SP analysis of prostate cancer cell lines DU145-TXR and PC3-TXR, respectively as well as the effect of treatment with PTX and CYA. Control DU145 cells have tiny amounts of SP (0.2%, Fig. 2A) while PTX resistant cell line DU145-TXR has ∼3.2% of SP cells (Fig. 2B) as indicated by Hoechst staining (p<0.05 compared to DU 145 cells). In case of PC3-TXR cells, nearly 2% of viable cells were gated as SP (Fig. 3A). Verapamil, a known suppressor of efflux pumps was used in these studies as a control to set up the gates in the FACS dot plots. As seen in Figures. 2C and 3B, verapamil treatment significantly reduced SP fractions in DU145-TXR cells to 0.89% and to 0.6% in PC3-TXR cells. This data is in agreement with the use of verapamil as a control drug for identifying and gating Hoechst-light cells in various cancer cells, including prostate cancer. While treatment with 1 µM PTX for 12 h increased the SP fraction to 7.8%, treatment with 20 µM CYA, a combination of CYA and PTX 24 h after removal of PTX for a similar time decreased SP fraction to ∼ 2% (Fig. 2, panels D, E and F, respectively) (p<0.05 in all samples). In PC3-TXR cells, the SP fraction was markedly reduced following treatment with CYA (Fig. 3C) or CYA and PTX combination (Fig. 3D). Real time RT PCR analysis indicates higher expression of pluripotency markers OCT4 and NANOG, and cancer stem cell markers CD133 and ALDH1 in SP fractions compared to non-SP (NSP) fractions in both DU145-TXR and PC3-TXR cells. Post-differentiation fate of SP cells was studied by real time RT-PCR and Hoechst staining after their isolation and re-culturing. These cells differentiated into a mix population comprising SP and NSP fractions which differed in their phenotype (Fig. 4, panels A and B, respectively). Expression analysis of post-differentiation mixed-populations indicates reduced transcripts of the ABC-transporter and cancer stemness marker ABCG2 and higher expression of cell proliferation marker minichromosome maintenance 7 (MCM7) compared to undifferentiated SP-fractions (Fig. 4D). Further treatment of post-differentiation SP populations with 25 µM CYA for 48 h resulted in the SP fraction significantly decreasing from 15.8% (panel E) to 0.6% (panel F, p<0.05). Table 1 shows the cell cycle analysis of the flow sorted SP and NSP cells. It was observed that, 62% NSP cells were in the G0-G1 and 30% in S phase in contrast to 71.5% and 21% for SP cells, respectively (p<0.05).
Gene and Protein Expression in DU 145-TXR Cells
Expression of P-glycoprotein (P-gp) was assessed by Western blotting. Proteins were separated by SDS-PAGE and probed with anti-P-gp antibody to determine changes in protein expression following treatments. Figure 5A indicates that treatment with 25 µM CYA or a combination of CYA (10 µM) and PTX (0.5 µM) were equally effective, while treatment with PTX (0.5 µM) alone was ineffective. Expression of GLI-1 (Hh-pathway marker), OCT-4 (pluripotency/stem cell marker) and CD133 (cancer stem cell marker) was assessed using real time RT-PCR method and calculating the fold changes with respect to the Cp values obtained in DU145-TXR cells. Figure 5B show an increased expression of GLI-1, OCT-4 and CD133 (p<0.05 for all genes compared to DU 145 cells).
Profiling of Prostate Cancer Cells Identifies miRNAs Altered in Chemoresistance
Recent studies have implicated various miRNAs such as let 7, miR 34a and miR 200c in regulating tumorigenesis and chemoresistance in humans [12], [15]. To establish whether chemoresistance to PTX in prostate cancer was regulated at the level of miRNAs, we studied the differential expression of several miRNAs known to be involved in various human cancers. The expression of eighty of the most common cancer-related miRNAs was simultaneously determined by a real time PCR method by adding template cDNA prepared from DU145, DU145-TXR as well as PC3 and PC3-TXR cells to 96-well plates containing miRNA specific primers. A ΔΔCt method was used to calculate fold changes using PTX-sensitive parental cells as controls. Figure 6A and B identifies the miRNAs whose expression is different between PTX-resistant and sensitive prostate cancer cells. As can be seen, several miRNAs such as 1, 18a, 138, 29b, 200c, 34a and 126 were downregulated while 193b, 30c, 155, 146a, 10b, 10a, 17, 125b, 373, 144 and 23b were upregulated in PTX-resistant cells with respect to parental cells. To confirm that our findings using this array methodology were accurate and that we were not reporting false positives, we validated our data by carrying out miScript primer assays on a select few of the differentially expressed miRNAs identified using the PCR array. Figure 6C lists the miRNAs used for data validation. As can be seen, a very high degree of concordance exists between the fold changes obtained through the array data and the validating primer assays. This suggests that our methodology for sample handling and data processing is correct and this increases our confidence in the validity of our approach.
To confirm that combination therapy is effective in targeting miRNAs involved in modulating chemoresistance, DU145-TXR cells were treated with a combination of PTX (0.5 µM) and CYA (10 µM) for 48 h and expression of miRs 200c and 34a was determined. Figure 6D demonstrates that combination therapy at concentrations effective in reducing cell viability and inducing apoptosis in PTX-resistant prostate cancer cells also upregulated two anticancer miRNAs involved in decreasing the spread of prostate cancer (34a) and increasing sensitivity to drugs like PTX (200c). While expression of miRNA 200c increased approximately 4 fold after treatment, there was nearly a 3-fold increase in miRNA 34a expression (p<0.05 compared to untreated control cells).
Expression Analysis of Gene Targets of miRNAs 200c and 34a
Since miRNAs act by either repressing or cleaving their target mRNAs, we carried out gene expression analysis of several known downstream targets of several miRNAs, including miR200c and 34a identified in our cell and tissue miRNA arrays. Figure 7 delineates these target genes and their expression patterns in DU145-TXR cells compared to DU145 cells. As can be seen, there is upregulation of miR 200c target genes like VIMENTIN (2.5 fold), TUBB-3 (5 fold), ZEB 1 (5 fold), and miR 34a targets like CD44 (6 fold) and SIRT1 (2.5 fold) while the expression of another miR200c target E-CADHERIN was downregulated in DU145-TXR cells. In addition, gene targets of several miRNAs differentially expressed in this study were altered in DU145-TXR cells as well. These include DNMT1 (1.5 fold), BAK1 (2.4 fold) and PUMA (2.5 fold) downregulation.
Confirmation of Cell Culture Studies in Clinical Samples
We also carried out SP fraction analysis and cancer miRNA profiling in clinical prostate tissues. SP fraction was analyzed by Hoechst staining as described earlier. Nearly 1% of total viable cells in prostate cancer tissue were SP cells (Fig. 8A), closely mirroring our findings in PTX-resistant prostate cancer cell lines. miRNA profiling of cancer tissue from a second patient was also carried out. For data analysis and subsequent validation, we used benign prostate tissue from a third patient biopsy as a normalization control. Similar to our results described earlier, we were able to identify several miRNAs such as miRs 17, let71, 31a, 193b, 29b, 155, let 7d, 9, 125b and 30 as being upregulated while miRs 145, 205, 34a, 126, 200c, 27b, 99a and 152 were downregulated in prostate cancer tissue (Fig. 8B). Further, there are a number of miRNAs that are common to our tissue and cell arrays in the present study. For example, not only are miRs 155, 29b, 34a, 200c, 193b and 17 differentially expressed in cell line miRNA analysis, their expression patterns too match those seen in the tissue arrays, thereby further validating our data obtained from chemoresistant cancer cells.
Discussion
Advanced prostate cancer is usually treated with drugs like paclitaxel and docetaxel which eradicate the bulk of cells within the tumor. This therapeutic regimen often leads to chemoresistance for which few treatment strategies currently exist. Most tumors are heterogeneous and are composed of bulk cancer cells and a small population of pluripotent stem cells that are capable of self-renewal, are chemoresistant and capable of maintaining the tumor [5], [7]. These cancer stem cells (CSCs) are the reason why most chemotherapy drugs eventually lose their efficacy. We have recently shown that combining the antimitotic drug PTX with an Her-2 inhibitor, such as lapatinib can reverse chemoresistance [22]. There is some evidence that lapatinib exerts its anticancer effects in part by targeting the niche population of CSCs [24].
In recent years, inhibitors of Hh pathway such as CYA have been investigated for treating various malignancies as dysregulation of this pathway is a key step in generation and sustainment of cancers [17], [19], [20]. In prostate cancer too, there is evidence that Hh-pathway is upregulated [25]. Androgen independent prostate cancer cells such as DU145 and PC-3 have higher expression of Hh pathway members than androgen-dependent cells such as LnCaP [26]. Higher Gli-1 gene expression in PTX resistant DU145-TXR cells (Fig. 6) was observed compared to non-resistant parental cells. This prompted us to study the effect of combining CYA with PTX to treat the PTX chemoresistant. Treatment of DU145-TXR cells with 0.5 µM PTX and 10 µM CYA reduced cellular proliferation and cell viability while apoptosis, as measured by AnnexinV-FITC staining, increased significantly after 48 h of treatment (Fig. 1). In accordance with our previous observations [22], 0.5 µM PTX alone was not effective in reducing viability of DU145-TXR cells or inducing significant levels of apoptosis. Even though CYA at 25 µM decreased cell viability significantly, this reduction was still less than that achieved with lower concentration of drugs used in combination therapy. This ability to decrease proliferation of cancer cells while utilizing significantly reduced amounts of highly toxic drugs is a potential advantage for improved chemotherapy.
Many prostate cancers relapse due to multi-drug resistance (MDR) caused by the over-expression of ATP-binding cassette transporter proteins. These transporters actively efflux chemotherapeutic drugs from tumor cells and decrease the intracellular drug concentration [8], [27]. Therefore, modulation of MDR transporters is a promising approach to overcome MDR [28], [29], [30]. We have determined the effect of monotherapy with PTX or CYA, and their combination on the P-gp protein expression which is one of the major efflux pump systems involved in chemoresistance [31], [32]. Figure 5 indicates that treatment with a combination of PTX and CYA (0.5 µM and 10 µM, respectively) was able to downregulate P-gp protein expression. Thus, supplementing PTX with CYA can eliminate the chemoresistance of androgen independent prostate cancer cells by possibly suppressing MDR and decreasing P-gp expression.
In addition to the P-gp system, chemoresistance is regulated by various other mechanisms, including cancer stem cells which are highly chemoresistant due to their ability to efflux chemotherapy drugs. Many current techniques used for characterization of these stem cells rely on the presence of cell surface markers such as CD133 and CD44 which were used to isolate these cells using a flow cytometry approach [5], [33]. However, this approach suffers from the fact that during processing, including trypsinization, many of these surface markers are cleaved and therefore not available for antibody binding. Further, CD 133 is not a reliable marker for isolating CSCs as its expression may not be restricted to cancer stem cells and that even CD 133− cells can initiate tumorigenesis [34]. For this reason, the vital dye Hoechst 33242 was used in the present study for separating SP from main population of cancer cells. The SP fractions are a subpopulation of CSCs which were first identified in a hematopoietic stem cell isolation procedure [9]. These cells have a unique fluorescence-activated cell sorting (FACS) signature and can be separated by a flow cytometer with a UV laser as they are distinct from cells that take up the Hoechst 33342 dye. The SP fraction is capable of sustained expansion ex vivo and can generate both SP and non-SP progeny. To understand the mechanism of chemoresistance in chemoresistant prostate cancer cells, we hypothesized that these cells are likely to contain a higher percentage of cells that are chemoresistant and therefore have increased ability to efflux chemotherapy drugs like PTX. Staining with Hoechst dye resulted in a creation of a typical flow cytometric dot plot profile where P4 gated region in Fig. 3 and P8 gated region in Fig. 4 is lightly stained compared to other cells. These lightly stained cells are the SP fraction which constitutes approximately 2–4% of total viable cells. In contrast, the parental PTX-sensitive DU145 cells had only 0.2% cells in the P4 region, thereby confirming our hypothesis of a distinct cell population with the ability to efflux hydrophobic drugs effectively, thereby inducing chemoresistance. Treatment with verapamil, an inhibitor of calcium gated channels, and known suppressor of cancer stem cells [35] significantly reduced SP fraction thereby confirming that the population being gated is indeed related to CSCs. It is a known fact that in relapsed tumors and metastatic cancers, there are an increased percentage of cancer stem cells and SP fractions. In the present case also, treatment of DU145-TXR cells with 1 µM PTX actually increased SP fraction to nearly twice that observed in untreated samples (7.7% vs 3.4%). These observations are supported by several lines of evidence that indicate the role played by Hh-pathway in maintaining stem cells, including cancer stem cells in various tumors [36], [37]. Further, treatment with Hh-inhibitors can reduce or eliminate tumorigenic stem cells [37], [38], [39]. The present data indicates that there is more expression of OCT 4, a marker for self-renewal and pluripotency and CD133, a general marker for cancer stem cells [5] in DU145-TXR cells. This emphasizes the potential reservoir of CSC like cells mixed with bulk cancer cells in the chemoresistant cell line. From the theory of biogenesis of CSCs, it is clear that SP fraction have the potential for asymmetric differentiation and can give rise to non-SP fractions which will go on to form the bulk tumor cells [5], [40]. To verify this theory in prostate cancer cells, pure SP and NSP fractions were isolated by flow sorting recultured and photographed. Fig. 4A and B are representative micrographs of isolated SP cells and NSP fractions. As can be seen, SP fraction has more elongated cells with typical fibroblastic phenotype while NSP cells were more rounded. Further, compared to the non-SP, the SP cells from PTX-resistant versions of both DU 145 and PC3 cells had higher gene expression of pluripotency markers OCT4 and NANOG [41] and increased expressions of cancer stem cell markers ALDH1 and CD133 (Fig. 4C). This is not surprising since CSCs, including SP fractions are capable of self-renewal and can therefore persist in cultures such as those established after flow-sorting. Comparison of expression of ABCG2 and MCM7 transcripts also differed significantly between SP fraction and their progeny mixed populations. While expression of efflux pump ABCG2 was higher in SP cells, proliferation marker MCM7 [42] was highly expressed in post-differentiated cells compared to initial SP cells suggesting the propensity of these cells for reduced proliferation. Even after differentiation, the number of SP-fraction cells was very high (almost 16%) which vanished after treatment with a high concentration of CYA (25 µM) for 48 h suggesting that suppression of Hh-pathway may be playing a role in their persistence and maintenance (Fig. 4E and F, respectively). Isolated SP and NSP fractions were also used to confirm the cell cycle stages. We have shown that more SP cells were in G0/G1 phase than non-SP cells (Table 1). This is in accordance with our gene expression data and studies from other workers who have demonstrated that the inherent stem cell like properties of SP population include a propensity for quiescent phase [21], [40]. This may be the reason CSCs can bypass the G1/S checkpoint and thus maintain their ability for self-renewal and remain pluripotent.
Recent studies have demonstrated that dysregulation of various miRNAs is associated with the etiology, metastasis and prognosis of various cancers including prostate cancer [13], [14]. So far, nearly 50 miRNAs have been reported to be significantly expressed in human prostate cancer but only a few have been linked directly to the pathology and progression of prostate cancer [43], [44]. To confirm the hypothesis that chemoresistance to PTX involves differential expression of miRNAs, a focused profiling of miRNAs known to be involved in various malignancies was carried out in DU145-TXR and PC3-TXR cells (Fig. 6A and B, respectively). Several miRNAs involved in prostate cancer and other malignancies were differentially expressed in chemoresistant prostate cancer cells. Significant among these include miR200c, miR34a and miR29b, all of which are downregulated in DU145-TXR cells. These data trends are in accordance with studies in literature which shows that miR34 is downregulated in prostate cancer and its experimental replenishment in cultured cells prevents metastasis and invasion [45]. miRNA200c, which is downregulated in DU145-TXR cells, is a tumor-suppressor miRNA known which maintains ‘epithelialness’ of cancer cells by preventing EMT and the assumption of an aggressive chemoresistant mesenchymal phenotype. A recent study by Cochrane et al. confirmed reduced expression of miR200c as being responsible for chemoresistance to microtubule stabilizers (such as taxanes) in endometrial, breast and ovarian cancer cells. In multi-drug resistant cancer cells, restoration of miR200c levels by transfection of its mimic restored chemosensitivity to PTX [15]. This observation is further supported by evidence that the loss of miR200c expression results in a highly aggressive, mesenchymal and chemoresistant phenotype in lung cancer cells [46]. In view of the findings described above, we decided to confirm the effect of our combination therapy on the expression of miR200c and miR34a (Fig. 6D). After treatment with 0.5 µM PTX and 10 µM CYA for 48 h, the expression of both miRs 200c and 34a were increased significantly, compared to non-treated TXR cells. It is therefore feasible that this increase in the levels of these miRNAs due to the combination therapy is responsible for the increased apoptosis and decreased cell proliferation (Fig. 1).
Expression analysis of select genes which are known targets of differentially expressed miRNAs, including miR200c and 34a was carried out to further support our miRNA data. [47]. Figure 7 details some miRNA target genes which are altered in DU145-TXR cells compared to the parental DU145 cells. SIRT-1 is suppressed by miR34a and is upregulated in prostate cancers following loss or downregulation of miR34a [48]. In wild type cells, downregulation of SIRT-1 by miR34a results in increased apoptosis [49]. This suggests that the greater resilience of TXR cells may be due this loss of miR34a. CD 44 is also a surface marker for CSCs [5] and it stands to reason that it will be upregulated in a cell line where miR34a is downregulated and where SP fraction cells are found in higher numbers. Downregulation of miRNA200c leads to an EMT transformation which is characterized by a loss of E-CADHERIN (E-CAD) and upregulation of VIMENTIN (VIM) [15]. In aggressively metastatic cell lines from breast, ovarian and endometrial cancers, E-CAD levels are suppressed by ZEB-1 which is upregulated as a result of suppression of miR200c. Downregulation of miR200c also increases the protein and gene levels of TUBB-3. It has been suggested that decreased protein levels of TUBB-3 protein correlate to increased cell death in response to microtubule-targeting agents such as PTX. DNMTa1 which is also upregulated is a target of miR29b and is regulated by global hypomethylation. Loss of miR29b results in upregulation of DNMTa1 at protein and gene levels in aggressive cancer cells [50] such as seen in the present study. Bak-1 which is downregulated in DU145-TXR cells is a target of miR125b, a known oncomir which confers chemoresistance to PTX in breast cancer cells through suppression of Bak-1 gene [51]. Another target of miR125b is PUMA which is a proapoptotic gene and is suppressed when miR125b is overexpressed in cancer cells [52].
Finally, to correlate and extrapolate the above findings to clinical studies, SP fraction analysis (Fig. 8A) and miRNA profiling of prostate cancer tissues (Fig. 8B) was performed. Presence of distinct SP fractions in clinical prostate cancer tissue is supportive of our cell culture data. Further, as several miRNAs which are verifiably altered in PTX-resistant cell lines, such as miR200c and miR34a, are similarly modified in a clinical prostate cancer sample, our hypothesis and the overall approach taken to confirm it are strengthened substantially
Conclusion
We have established that chemoresistance to PTX in DU145-TXR and PC3-TXR cells is possibly regulated by miRNAs which are differentially expressed when the PTX sensitive cell line is transformed to a resistant phenotype. miRNAs are known to regulate cancer stem cells, chemoresistance and EMT since CSCs possess a mesenchymal phenotype that allows them to be invasive. This crosstalk between miRNAs, cancer stem cells and the resulting physiologic processes such as metastasis and chemoresistance is explained in the schematic in Figure 9.
The present study thus suggests a strategy to restore chemosensitivity to drug-resistant cancer cells, thereby ensuring that cancers do not relapse due to generation of CSCs in tumors.
Acknowledgments
The authors would like to thank Mr. Michael Danquah for useful discussions.
Author Contributions
Conceived and designed the experiments: SS RIM SWB RWW. Performed the experiments: SS DC RM. Analyzed the data: SS DC SWB RIM. Contributed reagents/materials/analysis tools: RIM. Wrote the paper: SS DC SWB RIM.
Citation: Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI (2012) Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway. PLoS ONE7(6): e40021. https://doi.org/10.1371/journal.pone.0040021
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.A. JemalR. SiegelE. WardY. HaoJ. Xu2009Cancer statistics, 2009.CA Cancer J Clin59225249
2. van Brussel JP, Mickisch GH (2003) Multidrug resistance in prostate cancer. Onkologie 26: 175–181.JP van BrusselGH Mickisch2003Multidrug resistance in prostate cancer.Onkologie26175181
3. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN (1993) The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19: 351–386.R. PazdurAP KudelkaJJ KavanaghPR CohenMN Raber1993The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).Cancer Treat Rev19351386
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512.IF TannockR. de WitWR BerryJ. HortiA. Pluzanska2004Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med35115021512
5. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946–10951.AT CollinsPA BerryC. HydeMJ StowerNJ Maitland2005Prospective identification of tumorigenic prostate cancer stem cells.Cancer Res651094610951
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111–115.L. Ricci-VitianiDG LombardiE. PilozziM. BiffoniM. Todaro2007Identification and expansion of human colon-cancer-initiating cells.Nature445111115
7. Liu T, Xu F, Du X, Lai D, Zhao Y, et al. (2010) Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem 340: 265–273.T. LiuF. XuX. DuD. LaiY. Zhao2010Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.Mol Cell Biochem340265273
8. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234.G. SzakacsJK PatersonJA LudwigC. Booth-GentheMM Gottesman2006Targeting multidrug resistance in cancer.Nat Rev Drug Discov5219234
9. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797–1806.MA GoodellK. BroseG. ParadisAS ConnerRC Mulligan1996Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.J Exp Med18317971806
10. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101: 14228–14233.C. Hirschmann-JaxAE FosterGG WulfJG NuchternTW Jax2004A distinct “side population” of cells with high drug efflux capacity in human tumor cells.Proc Natl Acad Sci U S A1011422814233
11. Takubo K, Ohmura M, Azuma M, Nagamatsu G, Yamada W, et al. (2008) Stem cell defects in ATM-deficient undifferentiated spermatogonia through DNA damage-induced cell-cycle arrest. Cell Stem Cell 2: 170–182.K. TakuboM. OhmuraM. AzumaG. NagamatsuW. Yamada2008Stem cell defects in ATM-deficient undifferentiated spermatogonia through DNA damage-induced cell-cycle arrest.Cell Stem Cell2170182
12. Kent OA, Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188–6196.OA KentJT Mendell2006A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.Oncogene2561886196
13. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.F. YuH. YaoP. ZhuX. ZhangQ. Pan2007let-7 regulates self renewal and tumorigenicity of breast cancer cells.Cell13111091123
14. Zhang W, Dahlberg JE, Tam W (2007) MicroRNAs in tumorigenesis: a primer. Am J Pathol 171: 728–738.W. ZhangJE DahlbergW. Tam2007MicroRNAs in tumorigenesis: a primer.Am J Pathol171728738
15. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055–1066.DR CochraneNS SpoelstraEN HoweSK NordeenJK Richer2009MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.Mol Cancer Ther810551066
16. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, et al. (2007) Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524–2533.EE BarA. ChaudhryA. LinX. FanK. Schreck2007Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma.Stem Cells2525242533
17. Chung MK, Kim HJ, Lee YS, Han ME, Yoon S, et al. (2010) Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1. Clin Exp Med 10: 51–57.MK ChungHJ KimYS LeeME HanS. Yoon2010Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1.Clin Exp Med105157
18. Shaw G, Prowse DM (2008) Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int 8: 3.G. ShawDM Prowse2008Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling.Cancer Cell Int83
19. Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, et al. (2010) Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer 9: 89.M. ChenMA FeuersteinE. LevinaPS BaghelRD Carkner2010Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.Mol Cancer989
20. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, et al. (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431: 707–712.SS KarhadkarGS BovaN. AbdallahS. DharaD. Gardner2004Hedgehog signalling in prostate regeneration, neoplasia and metastasis.Nature431707712
21. Mimeault M, Johansson SL, Henichart JP, Depreux P, Batra SK (2010) Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther 9: 617–630.M. MimeaultSL JohanssonJP HenichartP. DepreuxSK Batra2010Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.Mol Cancer Ther9617630
22. Li F, Danquah M, Singh S, Wu H, Mahato RI (2011) Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Deliv and Transl Res 1: 420–428.F. LiM. DanquahS. SinghH. WuRI Mahato2011Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer.Drug Deliv and Transl Res1420428
23. Danquah M, Li F, III CBD, Miller DD, Mahato RI (2009) Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer. PharmRes 26: 2081–2092.M. DanquahF. LiCBD IIIDD MillerRI Mahato2009Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer.PharmRes2620812092
24. Nguyen NP, Almeida FS, Chi A, Nguyen LM, Cohen D, et al. (2010) Molecular biology of breast cancer stem cells: potential clinical applications. Cancer Treat Rev 36: 485–491.NP NguyenFS AlmeidaA. ChiLM NguyenD. Cohen2010Molecular biology of breast cancer stem cells: potential clinical applications.Cancer Treat Rev36485491
25. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, et al. (2004) Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 101: 12561–12566.P. SanchezAM HernandezB. SteccaAJ KahlerAM DeGueme2004Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling.Proc Natl Acad Sci U S A1011256112566
26. Nadendla SK, Hazan A, Ward M, Harper LJ, Moutasim K, et al. (2011) GLI1 confers profound phenotypic changes upon LNCaP prostate cancer cells that include the acquisition of a hormone independent state. PLoS One 6: e20271.SK NadendlaA. HazanM. WardLJ HarperK. Moutasim2011GLI1 confers profound phenotypic changes upon LNCaP prostate cancer cells that include the acquisition of a hormone independent state.PLoS One6e20271
27. Colabufo NA, Contino M, Berardi F, Perrone R, Panaro MA, et al. (2011) A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents. Toxicol In Vitro 25: 222–230.NA ColabufoM. ContinoF. BerardiR. PerroneMA Panaro2011A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.Toxicol In Vitro25222230
28. Baumert C, Hilgeroth A (2009) Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem 9: 415–436.C. BaumertA. Hilgeroth2009Recent advances in the development of P-gp inhibitors.Anticancer Agents Med Chem9415436
29. Coley HM (2010) Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 596: 341–358.HM Coley2010Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.Methods Mol Biol596341358
30. Shukla S, Ohnuma S, Ambudkar SV (2010) Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters. Curr Drug Targets. S. ShuklaS. OhnumaSV Ambudkar2010Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters.Curr Drug Targets
31. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P (2004) Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 68: 2043–2052.W. ChearwaeS. AnuchapreedaK. NandigamaSV AmbudkarP. Limtrakul2004Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder.Biochem Pharmacol6820432052
32. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV (2007) Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296: 85–95.P. LimtrakulW. ChearwaeS. ShuklaC. PhisalphongSV Ambudkar2007Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.Mol Cell Biochem2968595
33. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, et al. (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117: 3539–3545.GD RichardsonCN RobsonSH LangDE NealNJ Maitland2004CD133, a novel marker for human prostatic epithelial stem cells.J Cell Sci11735393545
34. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111–2120.SV ShmelkovJM ButlerAT HooperA. HormigoJ. Kushner2008CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.J Clin Invest11821112120
35. Komuro H, Saihara R, Shinya M, Takita J, Kaneko S, et al. (2007) Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J Pediatr Surg 42: 2040–2045.H. KomuroR. SaiharaM. ShinyaJ. TakitaS. Kaneko2007Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines.J Pediatr Surg4220402045
36. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, et al. (2007) Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 104: 4048–4053.CD PeacockQ. WangGS GesellIM Corcoran-SchwartzE. Jones2007Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.Proc Natl Acad Sci U S A10440484053
37. Singh BN, Fu J, Srivastava RK, Shankar S (2011) Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 6: e27306.BN SinghJ. FuRK SrivastavaS. Shankar2011Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms.PLoS One6e27306
38. Zhou Y, Yang J, Kopecek J (2012) Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 33: 1863–1872.Y. ZhouJ. YangJ. Kopecek2012Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells.Biomaterials3318631872
39. Ruiz IAA (2011) Hedgehog signaling and the gli code in stem cells, cancer, and metastases. Sci Signal 4: pt9.IAA Ruiz2011Hedgehog signaling and the gli code in stem cells, cancer, and metastases.Sci Signal4pt9
40. Yao J, Cai HH, Wei JS, An Y, Ji ZL, et al. (2010) Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol Rep 23: 1375–1382.J. YaoHH CaiJS WeiY. AnZL Ji2010Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells.Oncol Rep2313751382
41. Han J, Zhang F, Yu M, Zhao P, Ji W, et al. (2012) RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett. J. HanF. ZhangM. YuP. ZhaoW. Ji2012RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells.Cancer Lett
42. Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827–4833.MM HoAV NgS. LamJY Hung2007Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.Cancer Res6748274833
43. Baranwal S, Alahari SK (2010) miRNA control of tumor cell invasion and metastasis. Int J Cancer 126: 1283–1290.S. BaranwalSK Alahari2010miRNA control of tumor cell invasion and metastasis.Int J Cancer12612831290
44. Gandellini P, Folini M, Zaffaroni N (2010) Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discov Med 9: 212–218.P. GandelliniM. FoliniN. Zaffaroni2010Emerging role of microRNAs in prostate cancer: implications for personalized medicine.Discov Med9212218
45. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211–215.C. LiuK. KelnarB. LiuX. ChenT. Calhoun-Davis2011The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.Nat Med17211215
46. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, et al. (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207–1216.P. CeppiG. MudduluruR. KumarswamyI. RapaGV Scagliotti2010Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.Mol Cancer Res812071216
47. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, et al. (2005) Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 434: 338–345.X. XieJ. LuEJ KulbokasTR GolubV. Mootha2005Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals.Nature434338345
48. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114–119.Y. FujitaK. KojimaN. HamadaR. OhhashiY. Akao2008Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.Biochem Biophys Res Commun377114119
49. Yamakuchi M, Ferlito M, Lowenstein CJ (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 105: 13421–13426.M. YamakuchiM. FerlitoCJ Lowenstein2008miR-34a repression of SIRT1 regulates apoptosis.Proc Natl Acad Sci U S A1051342113426
50. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, et al. (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113: 6411–6418.R. GarzonS. LiuM. FabbriZ. LiuCE Heaphy2009MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.Blood11364116418
51. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, et al. (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496–21507.M. ZhouZ. LiuY. ZhaoY. DingH. Liu2010MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.J Biol Chem2852149621507
52. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, et al. (2011) miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 71: 538–549.XB ShiL. XueAH MaCG TepperHJ Kung2011miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.Prostate71538549
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2012 Singh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Many prostate cancers relapse due to the generation of chemoresistance rendering first-line treatment drugs like paclitaxel (PTX) ineffective. The present study aims to determine the role of miRNAs and Hedgehog (Hh) pathway in chemoresistant prostate cancer and to evaluate the combination therapy using Hh inhibitor cyclopamine (CYA). Studies were conducted on PTX resistant DU145-TXR and PC3-TXR cell lines and clinical prostate tissues. Drug sensitivity and apoptosis assays showed significantly improved cytotoxicity with combination of PTX and CYA. To distinguish the presence of cancer stem cell like side populations (SP), Hoechst 33342 flow cytometry method was used. PTX resistant DU145 and PC3 cells, as well as human prostate cancer tissue possess a distinct SP fraction. Nearly 75% of the SP cells are in the G0/G1 phase compared to 62% for non-SP cells and have higher expression of stem cell markers as well. SP cell fraction was increased following PTX monotherapy and treatment with CYA or CYA plus PTX effectively reduced their numbers suggesting the effectiveness of combination therapy. SP fraction cells were allowed to differentiate and reanalyzed by Hoechst staining and gene expression analysis. Post differentiation, SP cells constitute 15.8% of total viable cells which decreases to 0.6% on treatment with CYA. The expression levels of P-gp efflux protein were also significantly decreased on treatment with PTX and CYA combination. MicroRNA profiling of DU145-TXR and PC3-TXR cells and prostate cancer tissue from the patients showed decreased expression of tumor suppressor miRNAs such as miR34a and miR200c. Treatment with PTX and CYA combination restored the expression of miR200c and 34a, confirming their role in modulating chemoresistance. We have shown that supplementing mitotic stabilizer drugs such as PTX with Hh-inhibitor CYA can reverse PTX chemoresistance and eliminate SP fraction in androgen independent, metastatic prostate cancer cell lines.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer